These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35362143)

  • 41. Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?
    Ogura W; Ohtsuka K; Matsuura S; Okuyama T; Matsushima S; Yamasaki S; Miyagi H; Sekiguchi K; Ohnishi H; Watanabe T
    Viruses; 2022 May; 14(5):. PubMed ID: 35632698
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine.
    Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
    Fukushima J Med Sci; 2022 Apr; 68(1):67-70. PubMed ID: 35228456
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sex-associated differences between BMI and SARS-CoV-2 antibody titers following the BNT162b2 vaccine.
    Yamamoto S; Mizoue T; Tanaka A; Oshiro Y; Inamura N; Konishi M; Ozeki M; Miyo K; Sugiura W; Sugiyama H; Ohmagari N
    Obesity (Silver Spring); 2022 May; 30(5):999-1003. PubMed ID: 35226399
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
    Olariu TR; Ursoniu S; Marincu I; Lupu MA
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
    [No Abstract]   [Full Text] [Related]  

  • 45. The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients.
    Saiag E; Grupper A; Avivi I; Elkayam O; Ram R; Herishanu Y; Cohen Y; Perry C; Furer V; Katchman H; Rabinowich L; Ben-Yehoyada M; Halperin T; Baruch R; Goldshmidt H; Hagin D; Ben-Ami R; Sprecher E; Bomze D
    Clin Microbiol Infect; 2022 May; 28(5):735.e5-735.e8. PubMed ID: 35183747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
    Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
    Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Poor Antibody Response After Two Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine in Transplant Recipients.
    Mazzola A; Todesco E; Drouin S; Hazan F; Marot S; Thabut D; Varnous S; Soulié C; Barrou B; Marcelin AG; Conti F
    Clin Infect Dis; 2022 Mar; 74(6):1093-1096. PubMed ID: 34166499
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease.
    Bitzenhofer M; Suter-Riniker F; Moor MB; Sidler D; Horn MP; Gschwend A; Staehelin C; Rauch A; Helbling A; Jörg L
    PLoS One; 2022; 17(6):e0268780. PubMed ID: 35679232
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study.
    Nakashima K; Ishida M; Matsui H; Yoshida C; Nagai T; Shiraga M; Nakaoka H; Otsuka Y; Nakagama Y; Kaku N; Nitahara Y; Kido Y; Hirota Y
    Hum Vaccin Immunother; 2022 Nov; 18(6):2140549. PubMed ID: 36369871
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19.
    Cha HH; Lim SY; Kwon JS; Kim JY; Bae S; Jung J; Kim SH
    Korean J Intern Med; 2022 Mar; 37(2):455-459. PubMed ID: 35272444
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
    Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
    ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.
    Nam SY; Jeon SW; Lee HS; Lim HJ; Lee DW; Yoo SS
    JAMA Netw Open; 2022 May; 5(5):e2212996. PubMed ID: 35587345
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association between rubella vaccination response and long-term immune response to severe acute respiratory syndrome coronavirus 2 after BNT162b2 vaccination.
    Nakaharai K; Nakazawa Y; Yoshida M
    J Infect Chemother; 2024 Jan; 30(1):81-83. PubMed ID: 37659476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
    Herzog Tzarfati K; Gutwein O; Apel A; Rahimi-Levene N; Sadovnik M; Harel L; Benveniste-Levkovitz P; Bar Chaim A; Koren-Michowitz M
    Am J Hematol; 2021 Oct; 96(10):1195-1203. PubMed ID: 34185336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Humoral Response Following 3 Doses of mRNA COVID-19 Vaccines in Patients With Non-Dialysis-Dependent CKD: An Observational Study.
    Enilama O; Yau K; Er L; Atiquzzaman M; Oliver MJ; Romney MG; Leis JA; Abe KT; Qi F; Colwill K; Gingras AC; Hladunewich MA; Levin A
    Can J Kidney Health Dis; 2024; 11():20543581231224127. PubMed ID: 38292817
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between use of antipyretics and antibody titers after two doses of the BNT162b2 SARS-CoV-2 vaccine in adolescents and young adults with underlying diseases.
    Aiba H; Funaki T; Yamada M; Miyake K; Ueno S; Tao C; Myojin S; Matsui T; Ogimi C; Kato H; Miyairi I; Shoji K
    J Infect Chemother; 2024 Feb; 30(2):176-178. PubMed ID: 37769991
    [TBL] [Abstract][Full Text] [Related]  

  • 58. COVID-19 mRNA vaccines as hypothetical epigenetic players: Results from an in silico analysis, considerations and perspectives.
    Talotta R
    Vaccine; 2023 Aug; 41(35):5182-5194. PubMed ID: 37453842
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-spike protein antibody responses to BNT162b2 mRNA vaccine: A single-center survey in a COVID-19 non-epidemic area in Japan.
    Mokuda S; Kawanishi N; Kuroshima S; Kono J; Nakayama H; Mieno H; Kawamoto M
    Vaccine X; 2022 Aug; 11():100173. PubMed ID: 35692460
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody Titers After a Third and Fourth SARS-CoV-2 BNT162b2 Vaccine Dose in Older Adults.
    Eliakim-Raz N; Stemmer A; Ghantous N; Ness A; Awwad M; Leibovici-Weisman Y; Stemmer SM
    JAMA Netw Open; 2022 Jul; 5(7):e2223090. PubMed ID: 35862048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.